Search

Search Results

• 25 | EARLY AND MAINTAINED TREAT-TO-TARGET RESPONSE WITH IXEKIZUMAB UP TO 5 YEARS IN MODERATE-TO-SEVERE PSORIASIS: A POST-HOC ANALYSIS OF UNCOVER-3 E. Filippi¹, A. Armstrong², J. F. Merola³, M. Megna⁴, X. Man⁵, M. Honma⁶, J-M. Carrascosa⁷, R. Chughtai⁷, K. Fotiou⁸, S. Sabatino⁸, M. Ngantcha⁸, A. Pinter⁹ | ¹Eli Lilly Italia S.p.A, Florence, Italy; ²University of California, Los Angeles, CA, USA; ³University of Texas Southwestern Medical Center, Dallas, TX, USA; ⁴University of Naples Federico II, Naples, Italy; ⁵Zhejiang University, Hangzhou, China; ⁶Asahikawa Medical University, Asahikawa, Japan; ⁷Hospital Germans Trias, Universitat Autònoma de Barcelona, Barcelona, Spain; ⁸Eli Lilly and Company, Indianapolis, IN, USA; ⁹University Hospital Frankfurt, Frankfurt, Germany

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11087

  0

  PDF: 0

• The role of calcium serum level in clinical manifestation and progress of psoriasis vulgaris in a patient with Fahr’s syndrome

  Migena Vargu, Sabina Dedej, Petrit Vargu, Eriselda Kurushi, Anxhela Nisi, Samuele Vargu

  28-10-2025

  https://doi.org/10.4081/dr.2025.10614

  250

  PDF: 152

  HTML: 4
• 

  Autoinflammatory diseases: what is behind them and what is new?

  Michele Maalouly, Serena Saade, Mazen Kurban

  29-12-2022

  https://doi.org/10.4081/dr.2023.9625

  1871

  PDF: 590

  HTML: 159

• Mendelian randomization analysis of the causal association between metabolites and skin cancer

  Duanyu Wang, Minghao Tan, Nora Iv, Rattanaricky Ung, Gechhorng Lim, Vahid Say, Sokheng Phal, Pengkhun Nov

  12-03-2025

  https://doi.org/10.4081/dr.2025.10159

  578

  PDF: 407

  SUPPLEMENTARY MATERIAL: 156

  HTML: 12